D
Deciphera Pharmaceuticals Inc
F:D05
Deciphera Pharmaceuticals Inc
F:D05
Price:
53.93
EUR
-0.09%
Market Closed
Market Cap:
€4.4B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
D
|
Deciphera Pharmaceuticals Inc
F:D05
|
US |
|
Zett Corp
TSE:8135
|
JP |
|
Oryzon Genomics SA
MAD:ORY
|
ES |
|
G
|
Guangdong Huate Gas Co Ltd
SSE:688268
|
CN |
|
Interlife Holdings Co Ltd
TSE:1418
|
JP |
|
Maintel Holdings PLC
LSE:MAI
|
UK |
|
Thomson Reuters Corp
TSX:TRI
|
CA |
|
Loras Holding AS
IST:LRSHO.E
|
TR |
|
Cannamerica Brands Corp
OTC:CNNXF
|
CA |
Balance Sheet
Balance Sheet Decomposition
Deciphera Pharmaceuticals Inc
Deciphera Pharmaceuticals Inc
Balance Sheet Decomposition is not available for
Deciphera Pharmaceuticals Inc
Deciphera Pharmaceuticals Inc
Balance Sheet
Deciphera Pharmaceuticals Inc
Deciphera Pharmaceuticals Inc
Currency: USD
| Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Cash & Cash Equivalents |
26
|
57
|
197
|
294
|
120
|
106
|
87
|
65
|
84
|
|
| Cash Equivalents |
26
|
57
|
197
|
294
|
120
|
106
|
87
|
65
|
84
|
|
| Short-Term Investments |
0
|
0
|
0
|
0
|
459
|
446
|
199
|
260
|
223
|
|
| Total Receivables |
0
|
0
|
0
|
0
|
0
|
14
|
21
|
22
|
32
|
|
| Accounts Receivables |
0
|
0
|
0
|
0
|
0
|
14
|
21
|
22
|
32
|
|
| Other Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Inventory |
0
|
0
|
0
|
0
|
0
|
6
|
14
|
21
|
21
|
|
| Other Current Assets |
1
|
1
|
1
|
7
|
14
|
12
|
19
|
25
|
22
|
|
| Total Current Assets |
26
|
58
|
198
|
301
|
593
|
584
|
339
|
393
|
381
|
|
| PP&E Net |
0
|
1
|
1
|
13
|
27
|
46
|
45
|
43
|
37
|
|
| PP&E Gross |
0
|
1
|
1
|
13
|
27
|
46
|
45
|
43
|
37
|
|
| Accumulated Depreciation |
1
|
1
|
1
|
1
|
2
|
4
|
7
|
10
|
12
|
|
| Long-Term Investments |
0
|
0
|
0
|
0
|
0
|
9
|
42
|
15
|
47
|
|
| Other Long-Term Assets |
0
|
0
|
0
|
1
|
2
|
3
|
3
|
3
|
8
|
|
| Total Assets |
27
N/A
|
59
+120%
|
199
+238%
|
316
+58%
|
622
+97%
|
642
+3%
|
429
-33%
|
454
+6%
|
474
+4%
|
|
| Liabilities | ||||||||||
| Accounts Payable |
2
|
1
|
4
|
8
|
20
|
12
|
13
|
19
|
26
|
|
| Accrued Liabilities |
1
|
3
|
9
|
14
|
40
|
54
|
54
|
51
|
48
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Liabilities |
0
|
0
|
0
|
0
|
0
|
3
|
30
|
17
|
26
|
|
| Total Current Liabilities |
3
|
5
|
14
|
23
|
60
|
70
|
97
|
86
|
100
|
|
| Long-Term Debt |
2
|
1
|
1
|
1
|
0
|
0
|
0
|
0
|
0
|
|
| Other Liabilities |
0
|
0
|
0
|
12
|
16
|
29
|
28
|
26
|
22
|
|
| Total Liabilities |
5
N/A
|
6
+28%
|
15
+150%
|
36
+135%
|
76
+113%
|
99
+30%
|
125
+26%
|
112
-10%
|
123
+9%
|
|
| Equity | ||||||||||
| Common Stock |
137
|
193
|
0
|
0
|
1
|
1
|
1
|
1
|
1
|
|
| Retained Earnings |
120
|
146
|
196
|
296
|
488
|
754
|
1 054
|
1 233
|
1 428
|
|
| Additional Paid In Capital |
4
|
6
|
380
|
575
|
1 034
|
1 298
|
1 359
|
1 575
|
1 778
|
|
| Unrealized Security Profit/Loss |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Equity |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
|
| Total Equity |
22
N/A
|
53
+140%
|
184
+248%
|
280
+52%
|
546
+95%
|
544
-1%
|
305
-44%
|
342
+12%
|
351
+3%
|
|
| Total Liabilities & Equity |
27
N/A
|
59
+120%
|
199
+238%
|
316
+58%
|
622
+97%
|
642
+3%
|
429
-33%
|
454
+6%
|
474
+4%
|
|
| Shares Outstanding | ||||||||||
| Common Shares Outstanding |
31
|
31
|
33
|
38
|
52
|
58
|
59
|
68
|
81
|
|
Switch to:
Switch to:
See Also
Discover More
